



Company Presentation

NYSE American: KNW

September 15, 2022

Disclaimers



Safe Harbor Statement

This document contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2021, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at www.knowlabs.co. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.

Notice of Non-Affiliation and Disclaimer

Dexcom G6® is a registered trademark of Dexcom, Inc. Freestyle® is a registered trademark of Abbott Laboratories, Inc. Accu-Chek® is a registered trademark of Roche Diabetes Care, Inc. Know Labs is not affiliated, associated, authorized, endorsed by, or in any way officially connected with Dexcom, Abbott Laboratories or Roche Diabetes Care, or any of its subsidiaries or its affiliates.

Company Overview



Know Labs is **transforming medical diagnostics** and plans to launch the first truly non-invasive FDA cleared blood glucose monitoring device




Bio-RFID™, Know Labs proprietary diagnostic technology platform, uses radio waves to identify and measure what is going on inside the body

- **Form factor agnostic**: integrated into a variety of wearable, mobile or bench-top form factors
- **Pain-free**: no needles nor invasive transmitters poking the skin
- **No consumables**: potential to be 3x-5x less expensive than current FDA-cleared options
- **AI-Powered algorithms**: cutting-edge AI powering accurate predictive diagnosis (>95%)
- **Predictive health**: 100+ potential applications, beyond blood glucose monitoring

Product Portfolio

Efficient, Affordable and Completely Non-Invasive Medical Solutions

Audience: people with diabetes and pre-diabetes, and people with no diabetes but interested in monitoring their blood glucose levels



KnowU™
on-demand and on-the-go
spot glucose monitoring



UBand™
wearable
continuous glucose
monitoring



Know Labs Devices will connect to its smartphone App via Bluetooth and will be available on both the App Store and Google Play

Commercialization Pricing Targets

- Device + Monthly Subscription
- Under \$1K per year

Critical Development Steps

- Clinical Prototype
- FDA Pre-submission Meeting
- Multi-Site Clinical Trials
- FDA Breakthrough Designation
- FDA De Novo Pathway and Clearance (within 150 review days from application)


Bio-RFID Platform Opportunities

Analytes successfully identified by Bio-RFID


Glucose




Oxygen



Alcohol




Metabolized
Drugs



Multiple
research
opportunities

- Following FDA clearance, Know Labs plans to **expand Bio-RFID to other medical diagnostic applications**, including detecting and measuring levels of ketones, alcohol, vitamins, minerals and metabolized drugs
- Bio-RFID can proactively provide **useful and life saving data, enhancing health and patient care around the world.**

Pre-Clinical Internal Results – October 2021



- Bio-RFID average MARD was 5.8% when compared with the FDA-cleared devices used in the study (Accu-Chek® Fingerstick, Abbott FreeStyle® Libre and Dexcom G6®)
- These results confirm Bio-RFID can successfully measure blood glucose levels non-invasively and continuously
- Know Labs family of products can be an accurate and cost-effective alternative to the current FDA-cleared glucose monitoring devices



[Full Pre-Clinical Report](#)

Executive Leadership



Ron Erickson
Founder/Chairman

Former Chairman and CEO of eCharge Corporation, Chairman and Co-Founder of Blue Frog Mobile, Chairman and CEO of Global Tel Resources, and Chairman and CEO of Egghead Software.



Phil Bosua
Chief Executive Officer

Former Founder and CEO of LIFX, inventor of the world's first smart light bulb, and VP of Consumer Products at Soraa, the world's leading developer of solid-state lighting technology.




James Anderson, M.D.
Chief Medical Officer

Former Senior Medical Director, CardioMetabolic Medicine at Eli Lilly, Chief of Medicine at US Army Medical Research Institute for Infectious Diseases, Medical Director at PTS Diagnostics, Director, VoCare.



Pete Conley
CFO and SVP IP

34+ years of corporate finance and equity capital markets experience, more than \$5B in equity transactions, and over 20 years of specialization in strategic IP analysis, IP development, and IP monetization. Serves as Senior Managing Director and Head of Intellectual Property Banking at Boustead Securities.



Leo Trautwein
Chief Marketing Officer

20+ years of experience in corporate strategy, marketing, and e-commerce, having led multiple P&Ls and initiatives for Rivian Automotive, as well as Fortune 500 companies, including Jarden Corporation and Vista Outdoor.



Steven Kent
Chief Product Officer


10+ years of experience as an inventor, entrepreneur, and leader in medical and health-focused consumer systems. Most recently served as Head of Health Partnerships and Corporate Strategy at Oura. Founder and CEO of Invicta Medical, a medical technology company focused on sleep apnea treatment.




King Takee
SVP SW Engineering

20+ years of experience creating software for technology and healthcare companies. King leads Know Labs' software engineering, artificial intelligence, and machine learning activities.

Expected Path-to-Market



Why Know Labs?



Know Labs' Technology is in development, and there is no assurance that the development will have a successful outcome. Past performance is not indicative of future results. There is no guarantee that any specific objective will be achieved.

THANK YOU

www.knowlabs.co

ask@knowlabs.co

Know Labs, Inc.
NYSE American: KNW